Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research indicates for men evaluating prescription testosterone pathways heading into ...
Learn more about whether Halozyme Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
For more than 80 years, men have been told that testosterone fuels prostate cancer. But a more nuanced picture has emerged ...
The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.
It is expected that Herjuema, Celltrion's anticancer drug, will be able to be administered as a subcutaneous (SC) injection in under five minutes. Celltrion said on Dec. 8 that it plans to submit ...
A Food and Drug Administration panel of health experts convened Wednesday to discuss and promote the health benefits of testosterone treatments for men. FDA Commissioner Martin Makary told Morning ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.
The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...
The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback